Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.
Indian Pediatr
;
1995 Aug; 32(8): 855-61
Artigo
em Inglês
| IMSEAR
| ID: sea-9827
ABSTRACT
OBJECTIVES:
To assess efficacy and safety of oral iron chelating agent deferiprone (DFP) in patients with beta thalassemia and hemoglobin E-beta thalassemia.DESIGN:
Non-randomized study.SETTING:
Hematology Out-Patient Department.SUBJECTS:
Forty-one patients of beta thalassemia and hemoglobin E-beta thalassemia.INTERVENTIONS:
DFP was given to 20 patients, 10 patients of beta thalassemia and 10 with hemoglobin E-beta thalassemia; the rest were taken as controls.RESULTS:
A significant fall in serum ferritin was observed in the study group along with rise in urinary iron excretion (p < 0.05). Adverse effects of DFP were nausea and vomiting (30%), significant arthropathy requiring stopping of the drug (30%), and reversible neutropenia in one patient. All these complications could be managed easily with medical supervision and no death or permanent disability was seen.CONCLUSIONS:
DFP is an effective and fairly well tolerated oral iron chelating agent. The side effects that occur can be tackled easily if monitored properly.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Piridonas
/
Feminino
/
Humanos
/
Masculino
/
Hemoglobina E
/
Quelantes
/
Criança
/
Pré-Escolar
/
Administração Oral
/
Adolescente
Tipo de estudo:
Ensaio Clínico Controlado
País/Região como assunto:
Ásia
Idioma:
Inglês
Revista:
Indian Pediatr
Ano de publicação:
1995
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS